Vestipitant Or Vestipitant/Paroxetine Combination In Subjects With Tinnitus And Hearing Loss.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00394056

Recruitment Status : Completed

First Posted : October 31, 2006

Last Update Posted : October 28, 2016

Sponsor:

Information provided by (Responsible Party):

GlaxoSmithKline

Results Submitted - Not Posted on ClinicalTrials.gov

Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.

Recruitment Status :	Completed
Actual Primary Completion Date :	August 2009
Actual Study Completion Date :	August 2009

Submission Cycle	Results Submitted to ClinicalTrials.gov	Results Returned after Quality Control Review
1	July 13, 2017 (Canceled - Date Unknown) July 14, 2017	February 2, 2018
2	March 23, 2018 (Canceled on August 15, 2018)

Publications:

Claire Roberts, Amir Inamdar, Annelize Koch, Pauline Kitchiner, Odile Dewit, Emilio Merlo-Pich, Paolo Fina, Don J. McFerran & David M. Baguley. A Randomised, Double-blind, Placebo Controlled, Cross-over Study Comparing the Effects of Both Single and Repeated Dosing of Vestipitant or Vestipitant & Paroxetine in Treating Subjects with Moderate to Severe Tinnitus. [Otol Neurotol]. 2011;32(5):721-727.

To Top